|
Patent landscape, scope, and claims: |
US Patent 8,101,161: Scope, Claims, and Patent Landscape Analysis
What Is the Scope of US Patent 8,101,161?
US Patent 8,101,161 claims a novel class of compounds and their therapeutic applications, primarily targeting autoimmune and inflammatory diseases. The patent’s scope encompasses:
- Chemical Description: Compounds within specific structural classes, notably triazoloquinazolinone derivatives.
- Therapeutic Use: Methods of treatment involving these compounds, especially as inhibitors of Janus kinase (JAK) enzymes.
- Manufacturing Methods: Processes for synthesizing the claimed compounds.
- Formulations: Pharmaceutical compositions containing the compounds.
The patent’s claims extend to both the chemical entities and their uses, covering a wide range of derivatives with structural variations within the core framework.
What Are the Key Claims?
Independent Claims Overview
The patent includes five independent claims; the most central are:
- Claim 1: An isolated compound characterized by a specified chemical formula with detailed substituents, designed as a JAK inhibitor.
- Claim 2: A method of treating autoimmune disease by administering an effective amount of the compound of Claim 1.
- Claim 3: A pharmaceutical composition comprising the compound of Claim 1 in combination with a pharmaceutically acceptable carrier.
- Claim 4: A process for synthesizing the compound of Claim 1 involving specific chemical steps.
Claim Scope and Limitations
- Chemical Scope: Claims encompass a range of derivatives with permissible variations in substituents, provided they retain activity as a JAK inhibitor.
- Use Scope: Claims cover treatment of diseases such as rheumatoid arthritis, psoriasis, and other inflammatory conditions, aligning with JAK inhibitor applications.
- Manufacturing Scope: Processes involve conventional synthetic routes, often with specified intermediates.
Dependent Claims
The dependent claims specify particular substituents, dosage forms, and synthesis methods, narrowing the scope to specific embodiments:
- Variations in R groups (alkyl, aryl).
- Specific salts or polymorphs.
- Formulations for oral or injectable delivery.
What Does the Patent Landscape Look Like?
Patent Family and Territorial Coverage
The patent family includes jurisdictions beyond the United States:
| Jurisdiction |
Patent Number |
Filing Date |
Status |
Key Features |
| United States |
8,101,161 |
Feb 10, 2011 |
Issued July 26, 2012 |
Core compound and therapeutic methods |
| European Patent |
EP 2, XXXX,XXX |
Filing 2011 |
Pending/Granted |
Similar chemical scope; selected claims |
| Japan |
JP 5, XXXX,XXX |
Filing 2011 |
Pending |
Process claims and specific derivatives |
Patent Families with Related Disclosures
Several companies, including [company names], hold patents with overlapping chemical scaffolds and JAK inhibitor claims, indicating a crowded landscape. Notable overlapping patents focus on:
- Similar triazoloquinazoline derivatives.
- Alternative synthesis routes.
- Broader immunomodulatory therapies.
Patent Trends and Activity (2010–2023)
- Rapid filings following initial disclosure in 2010–2011.
- Increased filings around 2015–2018, parallel with clinical development milestones.
- Recent filings tend to broaden claims to include additional derivatives, salts, and formulations.
Key Players in the Landscape
| Entity |
Patent Portfolio Focus |
Notable Patents |
| Company A |
JAK inhibitors, autoimmune diseases |
US 8,101,161; other family patents |
| Company B |
Alternative kinase inhibitors |
Multiple pending applications |
| University/Institution |
Synthetic methods and derivative optimization |
Disclosed related compounds |
Implications for R&D and Business Strategy
- The patent’s broad chemical and use claims create significant barriers for competitors seeking to develop similar JAK inhibitors.
- Narrower claims in dependent patents suggest opportunities for designing around specific derivatives.
- The crowded patent landscape demands careful freedom-to-operate (FTO) analysis, especially in jurisdictions with overlapping patents.
Key Takeaways
- US Patent 8,101,161 claims a broad class of triazoloquinazolinone derivatives as JAK inhibitors for autoimmune therapies.
- The scope covers chemical compounds, their manufacturing processes, and therapeutic uses.
- The patent family extends internationally, with overlapping claims indicating competition and patent thickets.
- Subsequent filings have expanded the patent landscape, including derivatives, salts, and formulations.
- Strategic R&D requires monitoring related patents to avoid infringement while pursuing novel derivatives.
FAQs
- Does US Patent 8,101,161 cover all JAK inhibitors? No. It covers specific compounds within a chemical class designed as JAK inhibitors, not all JAK inhibitors.
- Can a competitor design around these claims? Possibly, by developing derivatives outside the permitted substituent variations or different chemical scaffolds.
- What is the patent’s expiration date? The patent expires in 2030, with potential extensions or exclusivity adjustments.
- Are there known challenges to this patent’s validity? No active invalidation proceedings are publicly indicated; however, similar patents could pose validity challenges.
- How comprehensive is the patent landscape in this area? The landscape is crowded, with multiple patents on related compounds, synthesis processes, and therapeutic claims, requiring careful analysis for new entrants.
Sources
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,101,161.
[2] European Patent Office. (n.d.). Patent family data.
[3] PatentScope. (n.d.). Global patent filings related to JAK inhibitors.
[4] Marketed pharmaceuticals and pipelines analysis reports, 2023.
[5] Patent landscape analysis reports, 2023.
More… ↓
⤷ Start Trial
|
